Zevra Therapeutics (ZVRA) Q2 2024 earnings summary

Executive summary

• Achieved key milestones in Q2 2024, including progress on arimoclomol for NPC, OLPRUVA commercial launch, and advancement of KP1077 for sleep disorders; completed the acquisition of Acer Therapeutics, adding OLPRUVA and celiprolol to the portfolio.

• FDA advisory committee voted favorably for arimoclomol as an effective treatment for NPC; PDUFA date set for September 21, 2024.

• KP1077 for idiopathic hypersomnia completed Phase 2, showing positive safety and efficacy signals, with an end-of-Phase 2 FDA meeting planned for Q3 2024.

• OLPRUVA launch continues, with increased reimbursement coverage, improved formulary status, and new patient enrollments in Q2 2024.

• Recent underwritten public offering raised $64.5 million, extending cash runway into Q1 2027 and supporting near-term catalysts.

Financial highlights

• Q2 2024 net revenue was $4.4 million, including $3.1 million from French EAP for arimoclomol and $1.3 million in royalties and reimbursements, down from $8.5 million in Q2 2023.

• Net loss for Q2 2024 was $19.9 million, or $0.48 per share, compared to $2.6 million, or $0.08 per share, in Q2 2023, reflecting increased commercial investments.

• R&D expenses for Q2 were $10.5 million, up from $7.4 million year-over-year, mainly due to KP1077 trial costs.

• SG&A expenses rose to $12.6 million from $6.6 million, reflecting commercial team expansion and OLPRUVA launch activities.

• Pro forma cash, cash equivalents, and investments as of June 30, 2024, were $113.8 million, including offering proceeds.

Outlook and guidance

• Cash runway now extends into Q1 2027, based on current operating plan and excluding potential arimoclomol revenue or Priority Review Voucher sale.

• Focused on three priorities: arimoclomol approval and launch, OLPRUVA launch, and pivotal KP1077 trial design.

• Preparing for anticipated U.S. launch of arimoclomol, pending FDA approval with PDUFA date set for September 21, 2024.

• Expect OLPRUVA enrollments to increase in the second half of 2024 as awareness grows.

• Revenue growth is expected to depend on regulatory approvals, product launches, and milestone/royalty payments from partnerships.